Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Biogen will work with Sangamo Therapeutics on gene regulation therapies for Alzheimer's, Parkinson's and other neurological diseases in a deal worth up to…
Biogen will pay Sangamo Therapeutics 350 million dollars upfront — including a 225 million dollar equity stake — and up to 2.37 billion dollars in milestones…
Sangamo Therapeutics disclosed in its 2023 year-end disclosures that the Biogen ZFP-TF gene regulation collaboration faced significant program-level…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Biogen and Sangamo announced a global licensing collaboration to develop and commercialize ST-501 for tauopathies, ST-502 for synucleinopathies, plus an undisclosed neuromuscular target and up to nine additional neurological targets. Sangamo received $350M upfront ($125M license fee plus $225M equity) and is eligible for up to $2.37B in development, regulatory and commercial milestones plus tiered royalties. UPDATE: The collaboration closed April 3, 2020. Biogen subsequently terminated the agreement effective June 15, 2023 following a strategic pipeline review, returning all rights (including ST-501 and ST-502) to Sangamo and prioritizing its Leqembi/lecanemab launch and tau ASO BIIB080. Sangamo lost eligibility for the remaining milestones and royalties from the $2.37B pool. Novartis terminated its parallel Sangamo deal at the same time (effective June 11, 2023).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Biogen Inc. / Sangamo Therapeutics, Inc. (this deal) | 2020 | $2.7B | — |
| Biogen Inc. / Reata Pharmaceuticals | 2023 | $7.3B | 73 |
| Biogen Inc. / Human Immunology Biosciences | 2024 | $1.1B | 68 |
| Biogen Inc. / RayThera Inc. | 2026 | $1.0B | 52 |
| Biogen Inc. / Bristol-Myers Squibb Company | 2017 | $710M | 15 |
| Biogen Inc. / Nightstar Therapeutics | 2019 | $800M | — |
| Biogen Inc. / TJ Biopharma Co., Ltd. | 2026 | $850M | — |
← Browse all deals · How we score deals
More: 2020 deals · Biogen Inc. deals · Neurology deals